Although it has not been adopted as a new strategy for kidney disease due to safety issues associated with some incident cases of heart failure, the role of the NRF2 activator, CDDO-Me, in diabetic nephropathy was examined in a phase 3 trial, and new phase 2 and 3 trials using CDDO-Me are ongoing. Here, NFE2L2 is linked to kidney disorder.